Letrozole
- Generic Name
- Letrozole
- Brand Names
- Femara, Kisqali Femara Co-pack
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11N5
- CAS Number
- 112809-51-5
- Unique Ingredient Identifier
- 7LKK855W8I
- Background
Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
Letrozole was granted FDA approval on 25 July 1997.
- Indication
Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer. Letrozole, given with ribociclib, is indicated to treat pre, peri, and postmenopausal...
- Associated Conditions
- Advanced Breast Cancer, Anovulatory cycle, Epithelial Ovarian Cancer, HR+, HER2-, Advanced Breast Cancer, Stage I Breast Cancer, Metastatic HR + HER2 - breast cancer
- Associated Therapies
- -
The Use of Letrozole or Mifepristone for Pretreatment of Medical Termination of Pregnancy
- Conditions
- Interventions
- First Posted Date
- 2022-04-22
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- KK Women's and Children's Hospital
- Target Recruit Count
- 144
- Registration Number
- NCT05341817
- Locations
- 🇸🇬
KK Women's and Children's Hospital, Singapore, Singapore
Comparison Between Letrozole and Mifepristone in Medical Termination of First Trimester Miscarriages
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- Calcutta National Medical College and Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT05304273
- Locations
- 🇮🇳
Calcutta National Medical College and Hospital, Kolkata, West Bengal, India
SMMART Adaptive Clinical Treatment (ACT) Trial
- Conditions
- Advanced Breast CarcinomaAnatomic Stage IV Breast Cancer AJCC v8Stage II Pancreatic Cancer AJCC v8Stage III Ovarian Cancer AJCC v8Advanced Prostate CarcinomaRecurrent Adult Soft Tissue SarcomaRecurrent Breast CarcinomaStage IV Ovarian Cancer AJCC v8Advanced Malignant Solid NeoplasmAdvanced Ovarian Carcinoma
- Interventions
- Drug: AlectinibDrug: AlpelisibDrug: AnastrozoleBiological: AtezolizumabBiological: BevacizumabProcedure: BiopsyProcedure: Biospecimen CollectionDrug: CapecitabineDrug: CarboplatinDrug: CobimetinibDrug: EntrectinibDrug: EribulinDrug: FulvestrantBiological: Hyaluronidase-zzxf/Pertuzumab/TrastuzumabDrug: IrinotecanDrug: LetrozoleDrug: Nab-paclitaxelDrug: NiraparibDrug: OlaparibDrug: PaclitaxelDrug: PalbociclibBiological: PertuzumabOther: Quality-of-Life AssessmentBiological: TrastuzumabBiological: Trastuzumab EmtansineDrug: VemurafenibDrug: VinorelbineDrug: Vismodegib
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- OHSU Knight Cancer Institute
- Registration Number
- NCT05238831
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
- Conditions
- Interventions
- First Posted Date
- 2022-02-07
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 35
- Registration Number
- NCT05226871
- Locations
- 🇨🇳
Mackay Memorial Hospital, Taipei, Taiwan
🇲🇽Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Monterrey, Nuevo LEÓN, Mexico
🇨🇳Hubei Cancer Hospital, Wuhan, Hubei, China
Randomized Controlled Trial of Combined Letrozole and Clomid (CLC II) Versus Letrozole Alone for Women With Anovulation
- Conditions
- Interventions
- First Posted Date
- 2022-01-25
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Rachel Mejia
- Target Recruit Count
- 189
- Registration Number
- NCT05206448
- Locations
- 🇺🇸
University of Iowa Hospitals & Clinics- West Des Moines Clinic, West Des Moines, Iowa, United States
🇺🇸University of Wisconsin, Madison, Wisconsin, United States
🇺🇸University of Iowa Hospitals & Clinics - Davenport Clinic, Davenport, Iowa, United States
Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 60
- Registration Number
- NCT05183828
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Roll-over Study to Allow Continued Access to Ribociclib
- Conditions
- Interventions
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 137
- Registration Number
- NCT05161195
- Locations
- 🇺🇸
Poudre Valley Hospital, Fort Collins, Colorado, United States
🇺🇸Ironwood Cancer and Research Centers, Chandler, Arizona, United States
🇺🇸Highlands Oncology Group, Fayetteville, Arkansas, United States
Vitamin D Supplementation and Improvement of PCOS Therapy and IVF Outcomes in Infertile Saudi Women
- First Posted Date
- 2021-11-04
- Last Posted Date
- 2021-11-04
- Lead Sponsor
- Umm Al-Qura University
- Target Recruit Count
- 700
- Registration Number
- NCT05106712
Efficacy of Letrozole Versus Clomiphene Citrate on Ovulation Induction in Patients With Polycystic Ovarian Syndrome
- First Posted Date
- 2021-10-13
- Last Posted Date
- 2021-10-14
- Lead Sponsor
- Nishtar Medical University
- Target Recruit Count
- 78
- Registration Number
- NCT05075863
- Locations
- 🇵🇰
Nishtar Medical University Hospital, Multan, Punjab, Pakistan
A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)
- Conditions
- Interventions
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT05035836
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.